SCHEMBL18860223

SCHEMBL18860223

CN1CCC2(CC1)CC2NC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 4/20 0.49
▸ CARM1 Q86X55 1/20 0.45
▸ PRMT6 Q96LA8 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ EZH2 Q15910 1/20 0.43
▸ CTSS P25774 1/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ADRA1D P25100 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ ADRA1B P35368 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18838368 0.82 CARM1 (0.46) SCN9ACARM1PRMT6KMT2AMEN1
SCHEMBL18838344 0.82 CYP2D6 (0.46) SCN9ACARM1PRMT6KMT2AALDH1A1
SCHEMBL18838506 0.82 HTR2A (0.54) KMT2AHDAC1HDAC6MEN1ADRA1A
SCHEMBL18838471 0.81 KCNH2 (0.56) KMT2AALDH1A1HDAC1HDAC6MEN1
SCHEMBL18838296 0.79 EZH2 (0.45) SCN9ANPC1RAB9AEZH2KMT2A
SCHEMBL18838394 0.78 LMNA (0.43) SCN9ACARM1PRMT6NPC1KMT2A
SCHEMBL9566447 0.77 HDAC1 (0.50) KMT2AHDAC1HDAC6MEN1
SCHEMBL18838340 0.76 SMN1; SMN2 (0.51) NPC1RAB9AKMT2AHDAC1HDAC6
SCHEMBL18838388 0.74 KCNH2 (0.46) SCN9ACARM1PRMT6
SCHEMBL363917 0.74 CARM1 (0.69) CARM1PRMT6NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed
Send feedback